Straits Times Index
3,321.95 -4.33 (-0.13%) Nikkei
39,693.50 +520.35 (+1.33%) Hang Seng
18,100.00 +27.10 (+0.15%) FTSE 100
8,247.79 -33.76 (-0.41%) Bitcoin USD
61,597.43 +503.41 (+0.82%) CMC Crypto 200
1,278.49 +29.37 (+2.35%)
LEGN Dec 2024 70.000 call
- Insider Monkey
Does Legend Biotech (LEGN) Have a Long Runway for Growth?
TimesSquare Capital Management, an equity investment management company, released its “U.S. Focus Growth Strategy” first-quarter investor letter. A copy of the letter can be downloaded here. In the first quarter, the strategy returned 11.72% (gross) and 11.49% (net) compared to 9.50% for the Russell Midcap Growth Index. The first-quarter performance was barbelled, particularly for U.S. […]
- Business Wire
Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA
SOMERSET, N.J., June 03, 2024--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today results for the first time from the Phase 2 CARTITUDE-2 Cohort D study in multiple myeloma patients. Results showed patients with less than a complete response (CR) after front-line autologous stem cell transplant (ASCT) experienced deep and durable responses following a single infusion of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) with or without lena
- Business Wire
Legend Biotech to Participate in the Jefferies Global Healthcare Conference
SOMERSET, N.J., May 29, 2024--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company’s Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York, NY on Thursday, June 6, 2024, at 10:30 a.m. ET.
